Monika Rieger

Title: Monika Rieger: Innovator in Pulmonary Administration

Introduction

Monika Rieger is a notable inventor based in Spiesen-Elversberg, Germany. She has made significant contributions to the field of pulmonary administration through her innovative work on liposomes. Her research focuses on enhancing the delivery of active substances via aerosolized liposomal formulations.

Latest Patents

Monika Rieger holds a patent for "Liposomes for pulmonary administration." This invention relates to liposomes that comprise at least one first and one second phospholipid, cholesterol, and at least one active substance and/or colorant. The first phospholipid is a phosphatidylcholine, preferably DSPC, while the second phospholipid can be a phosphatidylcholine or an ethanolamine, preferably selected from DMPC, DPPC, or DPPE. The patent outlines specific molar ratios for the phospholipids and cholesterol, as well as optimal sizes for the liposomes, which range between 0.05 µm and 5 µm. The invention also emphasizes the importance of atomization stability and transition temperature for effective pulmonary delivery.

Career Highlights

Throughout her career, Monika Rieger has worked with prominent companies in the biotechnology sector. She has been associated with Lung Biotechnology Inc. and Lung LLC, a wholly-owned subsidiary of United Therapeutics Corporation. Her work in these organizations has allowed her to advance her research and contribute to innovative solutions in pulmonary medicine.

Collaborations

Monika has collaborated with notable colleagues, including Tobias Gessler and Thomas Schmehl. These partnerships have fostered a collaborative environment that enhances the development of her innovative ideas.

Conclusion

Monika Rieger's contributions to the field of pulmonary administration through her patented liposomal formulations demonstrate her commitment to advancing medical technology. Her work continues to influence the development of effective therapies for respiratory conditions.